BioNTech (NASDAQ:BNTX) Now Covered by Analysts at Citigroup

Citigroup initiated coverage on shares of BioNTech (NASDAQ:BNTX) in a research note issued on Thursday,Briefing.com Automated Import reports. The firm set a “buy” rating and a $145.00 price target on the stock. Citigroup’s price target would suggest a potential upside of 44.55% from the stock’s current price.

A number of other analysts also recently commented on the company. Canaccord Genuity Group reissued a “buy” rating and issued a $171.44 price objective on shares of BioNTech in a research note on Tuesday. Evercore ISI raised BioNTech from an “in-line” rating to an “outperform” rating and boosted their price objective for the stock from $110.00 to $125.00 in a research note on Tuesday, November 19th. HC Wainwright reissued a “buy” rating and issued a $150.00 price objective on shares of BioNTech in a research note on Monday, November 18th. Berenberg Bank initiated coverage on BioNTech in a research report on Tuesday, November 19th. They set a “buy” rating and a $130.00 target price on the stock. Finally, BMO Capital Markets boosted their target price on BioNTech from $130.00 to $143.00 and gave the stock an “outperform” rating in a research report on Tuesday. Three investment analysts have rated the stock with a hold rating, fourteen have issued a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $143.73.

BioNTech Stock Up 2.0 %

Shares of BioNTech stock opened at $100.31 on Thursday. The business’s fifty day moving average price is $116.18 and its two-hundred day moving average price is $113.04. The company has a debt-to-equity ratio of 0.01, a current ratio of 7.33 and a quick ratio of 7.21. The company has a market capitalization of $24.05 billion, a P/E ratio of -47.77 and a beta of 0.30. BioNTech has a 1-year low of $76.53 and a 1-year high of $131.49.

BioNTech (NASDAQ:BNTX) last posted its quarterly earnings data on Monday, March 10th. The company reported $1.08 EPS for the quarter, topping analysts’ consensus estimates of $0.38 by $0.70. BioNTech had a negative return on equity of 2.35% and a negative net margin of 15.16%. The company had revenue of $1.19 billion for the quarter, compared to the consensus estimate of $1.24 billion. During the same quarter in the previous year, the business earned $1.90 EPS. The company’s quarterly revenue was down 19.5% compared to the same quarter last year. As a group, research analysts forecast that BioNTech will post -3.88 EPS for the current year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of BNTX. Jones Financial Companies Lllp grew its stake in BioNTech by 110.3% in the fourth quarter. Jones Financial Companies Lllp now owns 469 shares of the company’s stock valued at $53,000 after purchasing an additional 246 shares in the last quarter. Planning Capital Management Corp grew its stake in BioNTech by 45,000.0% in the third quarter. Planning Capital Management Corp now owns 451 shares of the company’s stock valued at $54,000 after purchasing an additional 450 shares in the last quarter. Quintet Private Bank Europe S.A. grew its stake in BioNTech by 823.5% in the fourth quarter. Quintet Private Bank Europe S.A. now owns 785 shares of the company’s stock valued at $88,000 after purchasing an additional 700 shares in the last quarter. Allianz SE purchased a new position in BioNTech in the fourth quarter valued at about $90,000. Finally, GAMMA Investing LLC grew its stake in BioNTech by 48.2% in the fourth quarter. GAMMA Investing LLC now owns 923 shares of the company’s stock valued at $105,000 after purchasing an additional 300 shares in the last quarter. Hedge funds and other institutional investors own 15.52% of the company’s stock.

About BioNTech

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.